M E M O R A N D U M Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Biologics Evaluation and Research
To: File of STN 125416_0 and Pratibha Rana
From: Nancy Kirschbaum, PhD, BLA Chair
Subject: Filing Memo: Original BLA for OctaplasLG™, pooled plasma (human), solvent detergent treated, STN 125416_0
Through: Tim Lee, Acting Chief, Laboratory of Hemostasis/DH/OBRR
CC: Review committee members: Mikhail Ovanesov, Ze Peng, M. Keith Wyatt, Harold Boxenbaum, Mitchell Frost, Jie He, Michael Brony, Christine Drabick, Jerald Mullersman, Renee Rees
Octapharma Pharmazeutika, GmbH (Octapharma) has submitted original biologics license application (BLA), STN 125416_0 to support market clearance in the US for OctaplasLG™, pooled plasma (human), solvent detergent treated.
Octapharma seeks to obtain a clinical indication for management of pre-operative or bleeding patients who require replacement of multiple plasma coagulation factors and the substitution of intentionally removed plasma (e.g. plasma exchange in patients with thrombotic thrombocytopenic purpura – TTP).
OctaplasLG™ will be manufactured at the following locations:
Octapharma Pharmazeutika Produktionsges.m.b.H
Oberlaaer Strasse 235
A-1100 Vienna, Austria
Based on preliminary review of STN 125416_0 by all committee members, this original BLA for OctaplasLG™, pooled plasma (human), solvent detergent treated may be filed.